Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 86-95

  Rancourt, Raymond C ^a   Veress, Livia A ^a   Ahmad, Aftab ^a   Hendry Hofer, Tara B ^a   Rioux, Jacqueline S ^a   Garlick, Rhonda B ^a   White, Carl W ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Airway; Coagulation; Inhalation; Lung injury; Sulfur mustard; TFPI

Indexed keywords

FIBRIN; IMMUNOGLOBULIN M; MESSENGER RNA; MUSTARD GAS; PROTHROMBIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

ACUTE LUNG INJURY; AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD ANALYSIS; DEATH; GAS EXCHANGE; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; INHALATION; LUNG LAVAGE; MALE; NONHUMAN; PULSE OXIMETRY; RAT; RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AIRWAY; COAGULATION; INHALATION; LUNG INJURY; SULFUR MUSTARD; TFPI;

ADMINISTRATION, INHALATION; AIRWAY OBSTRUCTION; ANIMALS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CHEMICAL WARFARE AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN; FIBRINOLYSIS; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; LIPOPROTEINS; MALE; MICRODISSECTION; MUSTARD GAS; PROTEINS; PROTHROMBIN; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RESPIRATORY INSUFFICIENCY;

EID: 84882754744     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.05.020     Document Type: Article

References (37)

1. Allon N., Amir A., Manisterski E., Rabinovitz I., Dachir S., Kadar T. Inhalation exposure to sulfur mustard in the guinea pig model: clinical, biochemical and histopathological characterization of respiratory injuries. Toxicol. Appl. Pharmacol. 2009, 241:154-162.
2. Bastarache J.A., Wang L., Wang Z., Albertine K.H., Matthay M.A., Ware L.B. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L874-L881.
3. Bertozzi P., Astedt B., Zenzius L., Lynch K., LeMaire F., Zapol W., Chapman H.A. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 1990, 322:890-897.
4. Cale J.M., Lawrence D.A. Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr. Drug Targets 2007, 8:971-981.
5. Carley W.W., Niedbala M.J., Gerritsen M.E. Isolation, cultivation, and partial characterization of microvascular endothelium derived from human lung. Am. J. Respir. Cell Mol. Biol. 1992, 7:620-630.
6. Chapman H.A., Stone O.L. A fibrinolytic inhibitor of human alveolar macrophages. Induction with endotoxin. Am. Rev. Respir. Dis. 1985, 132:569-575.
7. Creasey A.A., Chang A.C., Feigen L., Wun T.C., Taylor F.B., Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 1993, 91:2850-2860.
8. Gautum A., Vijayaraghavan R., Sharma M., Ganesan K. Comparative toxicity studies of sulfur mustard (2,2'-dichloro diethyl sulfide) and monofunctional sulfur mustard (2-chloroethyl ethyl sulfide), administered through various routes in mice. J Med CBR Def 2006, 4:1-21.
9. Grau G.E., de Moerloose P., Bulla O., Lou J., Lei Z., Reber G., Mili N., Ricou B., Morel D.R., Suter P.M. Haemostatic properties of human pulmonary and cerebral microvascular endothelial cells. Thromb. Haemost. 1997, 77:585-590.
10. Greene R. Pulmonary vascular obstruction in the adult respiratory distress syndrome. J. Thorac. Imaging 1986, 1:31-38.
11. Gustafson M.E., Junger K.D., Wun T.C., Foy B.A., Diaz-Collier J.A., Welsch D.J., Obukowicz M.G., Bishop B.F., Bild G.S., Leimgruber R.M., et al. Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli. Protein Expr. Purif. 1994, 5:233-241.
12. Harenberg J., Malsch R., Heene D.L. Tissue factor pathway inhibitor: proposed heparin recognition region. Blood Coagul. Fibrinolysis 1995, 6(Suppl. 1):S50-S56.
13. Herriott R.M., Anson M.L., Northrop J.H. Reaction of enzymes and proteins with mustard gas (bis(beta-chloroethyl)sulfide). J. Gen. Physiol. 1946, 30:185-210.
14. Hosseini K., Moradi A., Mansouri A., Vessal K. Pulmonary manifestations of mustard gas injury: a review of 61 cases. Ir. J. Med. Sci. 1989, 14:20-26.
15. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit. Care Med. 2003, 31:S213-S220.
16. Idell S., Peterson B.T., Gonzalez K.K., Gray L.D., Bach R., McLarty J., Fair D.S. Local abnormalities of coagulation and fibrinolysis and alveolar fibrin deposition in sheep with oleic acid-induced lung injury. Am. Rev. Respir. Dis. 1988, 138:1282-1294.
17. Idell S., Peters J., James K.K., Fair D.S., Coalson J.J. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J. Clin. Invest. 1989, 84:181-193.
18. Idell S., Mazar A., Cines D., Kuo A., Parry G., Gawlak S., Juarez J., Koenig K., Azghani A., Hadden W., McLarty J., Miller E. Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits. Am. J. Respir. Crit. Care Med. 2002, 166:920-926.
19. Kumar R., Beguin S., Hemker H.C. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb. Haemost. 1994, 72:713-721.
20. Lawley P.D., Brookes P. Molecular mechanism of the cytotoxic action of difunctional alkylating agents and of resistance to this action. Nature 1965, 206:480-483.
21. Lwaleed B.A., Bass P.S. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J. Pathol. 2006, 208:327-339.
22. McClintock S.D., Hoesel L.M., Das S.K., Till G.O., Neff T., Kunkel R.G., Smith M.G., Ward P.A. Attenuation of half sulfur mustard gas-induced acute lung injury in rats. J. Appl. Toxicol. 2006, 26:126-131.
23. Mozier N.M., Hoffman J.L. Biosynthesis and urinary excretion of methyl sulfonium derivatives of the sulfur mustard analog, 2-chloroethyl ethyl sulfide, and other thioethers. FASEB J. 1990, 4:3329-3333.
24. Ohkura N., Hiraishi S., Itabe H., Hamuro T., Kamikubo Y., Takano T., Matsuda J., Horie S. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region. Antioxid. Redox Signal. 2004, 6:705-712.
25. Papirmeister B. Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications 1991, CRC Press, Boca Raton.
26. Rancourt R.C., Veress L.A., Guo X., Jones T.N., Hendry-Hofer T.B., White C.W. Airway tissue factor-dependent coagulation activity in response to sulfur mustard analog 2-chloroethyl ethyl sulfide. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L82-L92.
27. Schultz M.J., Millo J., Levi M., Hack C.E., Weverling G.J., Garrard C.S., van der Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004, 59:130-135.
28. Somani S.M., Babu S.R. Toxicodynamics of sulfur mustard. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989, 27:419-435.
29. Szinicz L. History of chemical and biological warfare agents. Toxicology 2005, 214:167-181.
30. Valentin S., Ostergaard P., Kristensen H., Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coagul. Fibrinolysis 1991, 2:629-635.
31. Van Den Boogaard F.E., Brands X., Schultz M.J., Levi M., Roelofs J.J., Van't Veer C., Van Der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J. Thromb. Haemost. JTH 2011, 9:122-132.
32. Veress L.A., O'Neill H.C., Hendry-Hofer T.B., Loader J.E., Rancourt R.C., White C.W. Airway obstruction due to bronchial vascular injury after sulfur mustard analog inhalation. Am. J. Respir. Crit. Care Med. 2010, 182:1352-1361.
33. Veress L.A., Hendry-Hofer T.B., Loader J.E., Rioux J.S., Garlick R.B., White C.W. Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction. Am. J. Respir. Crit. Care Med. 2013, 48:439-447.
34. Welty-Wolf K.E., Carraway M.S., Idell S., Ortel T.L., Ezban M., Piantadosi C.A. Tissue factor in experimental acute lung injury. Semin. Hematol. 2001, 38:35-38.
35. Winternitz M.C. Anatomical changes in the respiratory tract initiated by irritating gases. Military Surgeon 1919, 44:476-493.
36. Zeerleder S., Schroeder V., Hack C.E., Kohler H.P., Wuillemin W.A. TAFI and PAI-1 levels in human sepsis. Thromb. Res. 2006, 118:205-212.
37. Zeltner T.B., Bertacchini M., Messerli A., Burri P.H. Morphometric estimation of regional differences in the rat lung. Exp. Lung Res. 1990, 16:145-158.